<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518634</url>
  </required_header>
  <id_info>
    <org_study_id>2011-004294-87</org_study_id>
    <nct_id>NCT01518634</nct_id>
  </id_info>
  <brief_title>Imipramine Treatment for Patients With Multi-organ Bodily Distress Syndrome</brief_title>
  <acronym>Stress-3</acronym>
  <official_title>Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to test the effect of the tricyclic antidepressant Imipramine in&#xD;
      patients with longlasting health problems with no known medical explanation, defined as&#xD;
      multi-organ Bodily distress syndrome (BDS). Pharmacological treatment of patients with BDS&#xD;
      have never been tested, and Imipramine i low dosage (10-75 mg) has the potential of reducing&#xD;
      both pain and other symptoms of bodily distress for patients with BDS. Control conditions are&#xD;
      pill placebo. Study duration is 19 weeks for each of the 140 patients. End point is 13 weeks,&#xD;
      i.e. after 10 weeks of 25-75 mg study drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to test the effect of Imipramine in patients with multi-organ Bodily&#xD;
      distress syndrome (BDS). BDS is a unifying diagnosis that encompasses a group of closely&#xD;
      related conditions such as somatization disorder, fibromyalgia, irritable bowel syndrome and&#xD;
      chronic fatigue syndrome. The project consists of a double-blinded placebo controlled trial&#xD;
      of treatment with the tricyclic antidepressant Imipramine in dosages of 25-75 mg. Primary&#xD;
      outcome is patient-rated improvement measured by Clinical Global Improvement Scale (CGI-I).&#xD;
      Secondary outcome is functional level (physical, mental and social) measured by the SF-36&#xD;
      Physical Component Summary (PCS). The study requires 140 participants and study duration is&#xD;
      19 weeks for each patient. End point is 13 weeks, i.e. after 10 weeks of 25-75 mg study drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global Clinical Improvement Scale</measure>
    <time_frame>After 13 weeks</time_frame>
    <description>Questionnaire, patient-rated improvement of health since the beginning of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
    <description>Questionnaire, patient-rated. Assessment of physical, social and mental functioning</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for pain and worst symptom</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Checklist (SCL)</measure>
    <time_frame>At 1, 3 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Illness Checklist (FIC)</measure>
    <time_frame>At 1, 3 and 13 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHODAS II</measure>
    <time_frame>At 1 and 13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Somatisation Disorder</condition>
  <condition>Somatoform Disorders</condition>
  <arm_group>
    <arm_group_label>Imipramine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine treatment</intervention_name>
    <description>Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.</description>
    <arm_group_label>Imipramine treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. First time refered patients fulfilling diagnostic criteria for BDS multi-organ type&#xD;
             with symptoms for more than 3 of 4 symptom categories&#xD;
&#xD;
          2. Moderate or severe impact on daily life&#xD;
&#xD;
          3. Symptoms lasting for at least 2 years&#xD;
&#xD;
          4. Age 20-50 years&#xD;
&#xD;
          5. Born in Denmark or have Danish parents. The patient understands, speaks, writes and&#xD;
             read Danish.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence og other physical of psychiatric condition, if the symptoms of this condition&#xD;
             can not clearly be separated from symptoms of BDS&#xD;
&#xD;
          2. Current moderate or severe depression, patients in continuous antidepressant treatment&#xD;
             because of moderate or severe depression, and patients with other severe psychiatric&#xD;
             disorder that demands treatment, or if the patient is suicidal.&#xD;
&#xD;
          3. A lifetime-diagnosis of psychoses, mania or depression with psychotic symptoms&#xD;
             (ICD-10: F20-29, F30-31, F32.3, F33.3)&#xD;
&#xD;
          4. Abuse of alcohol, narcotics or drugs&#xD;
&#xD;
          5. Pregnancy, breastfeeding or current pregnancy wish. Fertile women must use effective&#xD;
             anticonception, (hormonal contraception, contraceptive injection, implant or patches,&#xD;
             intrauterine system and device, vaginal ring).&#xD;
&#xD;
          6. Treatment with all pain modulating drugs, e.g. all analgesics, antidepressants,&#xD;
             antiepileptica and other types of medication with pain relieving properties must be&#xD;
             discontinued at least two weeks before the treatment phase.&#xD;
&#xD;
          7. Imipramine treatment in sufficient dosage within the last year, i.e. 25 mg daily&#xD;
             continuously for at least 8 weeks.&#xD;
&#xD;
          8. Allergy to study medication or excipients in study medication.&#xD;
&#xD;
          9. Patients with previous med myocardial infarction, congestive heart failure, signs of&#xD;
             conduction defects or abnormalities on ECG (first degree AV-block, bundle branch block&#xD;
             or prolonged QT-interval), narrow-angle glaucoma, porphyria, inherited galactose&#xD;
             intolerance, epilepsy, hepatic insufficiency and severe renal impairment&#xD;
&#xD;
         10. Simultaneous use of:&#xD;
&#xD;
               -  antipsychotics&#xD;
&#xD;
               -  oral anticoagulants&#xD;
&#xD;
               -  diuretics&#xD;
&#xD;
               -  sympathomimetics and CNS-stimulating drugs (amphetamine-like drugs)&#xD;
&#xD;
               -  all serotonergic drugs, e.g. SSRI, SNRI and TCA, the dietary supplement hypericum&#xD;
                  perforatum, non-selective, irreversible or selective, reversible monoamine&#xD;
                  oxidase (MAO) inhibitors, triptans, tramadol, pethidin and tryptophan&#xD;
&#xD;
               -  the drugs cimetidine (H2-antagonist), quinidine (antiarrythmics), clonidine&#xD;
                  (antihypertensive), fluconazol (antimycotics), clindamycin, clarithromycin,&#xD;
                  erythromycin (antibiotics), droperidol (anaesthetic), levodopa (antiparkinson),&#xD;
                  mefloquine (antimalaria), phenytoin, barbiturates, carbamazepin (antiepileptica)&#xD;
&#xD;
               -  Bupropion (tobacco dependence), celecoxib (NSAID), cinacalcet (antiparathyroid&#xD;
                  drug), duloxetine (SNRI), flufenazin (antipsychotic), fluoxetin (SSRI), gefitinib&#xD;
                  (antineoplastic), moclobemid (MAO), paroxetine, Sertraline (SSRI), Terbinafine&#xD;
                  (antimycotics), Yohimbin (erectile dysfunction) samt fluvoxamin (SSRI),&#xD;
                  ciprofloxacin and enoxacin (microbiotic), because plasma concentration of&#xD;
                  Imipramine can increase with the simultaneous use of these potent CYP2D6- and&#xD;
                  CYP1A2- inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per k Fink, dr.med</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Clinic for Functional Disorders</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Agger JL, Schröder A, Gormsen LK, Jensen JS, Jensen TS, Fink PK. Imipramine versus placebo for multiple functional somatic syndromes (STreSS-3): a double-blind, randomised study. Lancet Psychiatry. 2017 May;4(5):378-388. doi: 10.1016/S2215-0366(17)30126-8. Epub 2017 Apr 10. Erratum in: Lancet Psychiatry. 2017 Jul;4(7):516.</citation>
    <PMID>28408193</PMID>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>May 8, 2017</last_update_submitted>
  <last_update_submitted_qc>May 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bodily Distress Syndrome</keyword>
  <keyword>Medically unexplained symptoms</keyword>
  <keyword>Functional somatic symptoms</keyword>
  <keyword>Functional somatic syndromes</keyword>
  <keyword>Treatment</keyword>
  <keyword>Imipramine</keyword>
  <keyword>Tricyclic antidepressant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

